Secchi, O., A. Franchi, and A. Lunello. “Comments to ‘Cost Per Responder for Vedolizumab and Ustekinumab in Crohn’s Disease Patients After Failure of TNF-α Inhibitors in Italy’”. AboutOpen, vol. 10, no. 1, June 2023, pp. 82-86, doi:10.33393/ao.2023.2600.